Guinea-Bissau's vaccine trial halt exposes US diplomacy crisis

Guinea-Bissau drew a line in the sand.

A US-backed hepatitis B vaccine trial targeting African newborns has been halted after the government of Guinea-Bissau refused to grant approval. The reversal is significant not because the science was sound — most independent experts called the trial’s central hypothesis fanciful — but because it reveals how American public health diplomacy is being reshaped by domestic political forces, and what happens when those forces meet a host country that has learned to say no.

Frederik Schaltz-Buchholzer, the Danish researcher who led the study, confirmed on LinkedIn that the trial will not move forward in Guinea-Bissau, stating only that the necessary governmental approval was not granted. The country’s Health Minister, Quinhin Nantote, had previously dismissed the idea that the project would proceed anyway, calling reports to the contrary entirely false. Within days, government agents searched the offices of the Bandim Health Project and took possession of the researchers’ vaccine supplies. The message was unmistakable: Guinea-Bissau is not a research lab.

The science was dubious. The politics are uglier.

The trial was funded with $1.6 million from the US Centers for Disease Control and Prevention and another $1.6 million from private partners including the Bill Ackman-backed Pershing Square Foundation and the Bluebell Foundation. That combined $3.2 million was meant to test a hypothesis that has little support in mainstream immunology: that giving the hepatitis B vaccine alongside live vaccines like BCG might blunt the non-specific mortality benefits those live vaccines appear to confer.

Paul Offit, a vaccines expert at the Children’s Hospital of Philadelphia, called the premise biologically incoherent. Hepatitis B is a single protein among billions the immune system encounters daily. There is no evidence it dampens the effects of other vaccines, and decades of global vaccination data show the opposite — that birth-dose hepatitis B vaccination dramatically reduces chronic infection and liver cancer.

Offit’s criticism cuts to a deeper point. Guinea-Bissau suffers one of the highest burdens of chronic hepatitis B in the world. The WHO recommends that every infant receive the first dose within 24 hours of birth, followed by at least two additional doses. The country currently plans to launch a universal birth-dose program in 2028 — two years away. While that timeline stretches ahead, thousands of newborns will go unprotected. The trial’s cancellation does not create that gap, but it also does not close it.

Consent that wasn’t.

One of the most uncomfortable details involves the trial’s design. Participants would have been randomized — half receiving the hepatitis B birth dose, half not. Parents who declined to participate would have received nothing. Henrik Støvring, a Danish researcher who has co-published work questioning earlier Bandim Health Project findings, framed the problem plainly: for a mother in Guinea-Bissau, opting into the study offered a 50 percent chance her child would get vaccinated, while opting out meant zero chance. That is not informed consent. It is coercion dressed as scientific inquiry.

The community backlash was swift. Residents wondered aloud whether a vaccine with a decades-long safety record was being tested on African children precisely because Western regulators considered it risky. Schaltz-Buchholzer acknowledged the perception, writing that the cancellation confirmed to many that the study challenged prevailing medical assumptions about birth vaccination. He insisted the vaccine schedule was not dangerous. Experts like Offit agreed — but the damage to trust was already done.

RFK Jr. and the reshaping of US health diplomacy.

The CDC’s decision to fund this trial deserves scrutiny beyond its scientific flaws. The agency’s global health budget is supposed to advance evidence-based interventions that reduce disease burden. Instead, millions were directed toward a hypothesis that contradictstood the established standard of care for a country desperate for it. That divergence between stated public health goals and actual funding priorities is the kind of contradiction that feeds suspicion across the Global South — suspicion that Western medical aid serves agendas other than the health of the people it claims to help.

Robert F. Kennedy Jr., who has risen to prominence through anti-vaccine activism before entering positions of influence in the Trump administration, has increasingly shaped the discourse around vaccine policy in the United States. While there is no public evidence he directly influenced this particular trial, the cultural and political climate he helped construct — one in which vaccine skepticism is normalized and mainstream medical consensus is treated as negotiable — creates the conditions under which well-funded but scientifically fringe proposals can attract federal dollars.

The trial’s funders tell a related story. The Pershing Square Foundation, backed by hedge fund magnate Bill Ackman, has a track record of funding unconventional health initiatives. Its involvement alongside the CDC suggests a partnership model in which private philanthropy can amplify projects that might not survive peer review at a public health agency alone. That is not inherently problematic, but it raises questions about accountability: who answers when a trial designed in Washington and funded by a mix of government and private money provokes outrage in Bissau?

What happens next.

Guinea-Bissau now controls the seized vaccines. Whether they will be used for the national immunization program remains unclear. The CDC has not said whether the $1.6 million it contributed will be redirected toward the universal birth-dose rollout that the WHO recommends. The WHO, through spokesperson Tarik Jašarević, reaffirmed its commitment to working with Guinea-Bissau’s authorities to ensure newborns receive timely hepatitis B protection — but the agency’s response stopped short of addressing how the trial itself came to be approved for funding in the first place.

The trial’s cancellation is a victory for Guinea-Bissau’s sovereignty. It is also an indictment of a system that allowed a medically unnecessary experiment on vulnerable infants to advance this far. The real question is whether the United States will treat this as a cautionary episode — an example of how domestic political currents can distort global health work — or whether it will simply move on to the next country, the next hypothesis, the next round of funding that puts prestige ahead of people.

Guinea-Bissau proved it can resist. The harder test is whether Washington learns to do better.